I am very pleased to introduce the latest article, “Identifying Skin Malignancies On The Distal Lower Extremity,” in our new CE series. This series, brought to you by HMP Communications, consists of regular CE activities that qualify for one continuing education contact hour (.1 CEU). Readers will not be required to pay a processing fee for this course.
Benign and malignant lesions may appear similar on the surface. Indeed, understanding the clinical characteristics of various lesions, making the right call on key diagnostic measures and making an appropriate referral can go a long way toward early detection for your patients.
Utilizing a case study-driven approach, James Q. Del Rosso, DO, FAOCD, describes characteristics of various types of lesions and essential diagnostic pearls for separating benign lesions from malignant ones.
At the end of this article, you’ll find a 10-question exam. Please mark your responses on the postage-paid postcard and return it to HMP Communications. This course will be posted on Podiatry Today’s Web site (www.podiatrytoday.com) roughly one month after the publication date. I hope this CE series contributes to your clinical skills.
Jeff A. Hall
INSTRUCTIONS: Physicians may receive one continuing education contact hour (.1 CEU) by reading the article on pg. 68 and successfully answering the questions on pg. 72. Use the postage-paid card provided to submit your answers or log on to www.podiatrytoday.com and respond electronically.
ACCREDITATION: HMP Communications, LLC is approved by the Council on Podiatric Medical Education as a sponsor of continuing education in podiatric medicine.
DESIGNATION: This activity is approved for 1 continuing education contact hour or .1 CEU.
DISCLOSURE POLICY: All faculty participating in Continuing Education programs sponsored by HMP Communications, LLC are expected to disclose to the audience any real or apparent conflicts of interest related to the content of their presentation.
DISCLOSURE STATEMENTS: Dr. Del Rosso has disclosed that he is a member of the Speaker’s Bureau for 3M Pharmaceuticals, Dermik Laboratories, Bioglan Pharmaceuticals and Allergan.
GRADING: Answers to the CE exam will be graded by HMP Communications, LLC. Within 60 days, you will be advised that you have passed or failed the exam. A score of 70 percent or above will comprise a passing grade. A certificate will be awarded to participants who successfully complete the exam.
TARGET AUDIENCE: Podiatrists.
RELEASE DATE: September 2003.
EXPIRATION DATE:September 30, 2004.
LEARNING OBJECTIVES: At the conclusion of this activity, participants should be able to:
• discuss differential diagnoses for slow-growing, exophytic nodules;
• identify clinical characteristics of squamous cell carcinoma in situ;
• identify clinical characteristics of melanoma;
• discuss appropriate diagnostic measures for confirming clinical suspicions of melanoma; and
• detect eccrine poroma and discuss treatment options for the condition.
Sponsored by HMP Communications, LLC.